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1. Introduction 
The widespread use of abdominal cross-sectional imaging such as computed tomography 
(CT) and magnetic resonance imaging (MRI) has resulted in a significant rise in the 
frequency of incidentally detected renal masses (Mouraviev et al., 2006). Most tumors are 
small and localized renal tumors have been shown to be of a very early clinical stage. It is 
estimated that in 2009, 57,760 new cases of kidney caner will be diagnosed and 12,980 
patients will die of the disease in the United States (American Cancer Society, 2009). 
Nephron-sparing surgery such as partial nephrectomy remains the gold standard in patients 
with small renal cell carcinomas (RCCs), with oncologic outcomes similar to the use of a 
radical nephrectomy (Bandi et al., 2008). However, both open and laparoscopic partial 
nephrectomy are associated with a significant complication rate and laparoscopic partial 
nephrectomy is also associated with a significant learning curve, increased warm ischemia 
time, and a higher morbidity rate as compared with open partial nephrectomy (Gill et al., 
2003). Many cases with incidentally detected small renal tumors are found in elderly 
patients with significant comorbidities, and these patients may not be good surgical 
candidates. Therefore, several investigators have utilized a variety of energy-based tissue-
ablative technologies such as radiofrequency (RF) ablation, cryoablation, high-intensity 
focused ultrasound, microwave thermotherapy, and interstitial photon irradiation as 
alternative treatment options of small renal masses (McAchran et al., 2005). Among these 
minimally invasive ablative techniques, RF ablation and cryoablation are the most 
commonly utilized methods and have been extensively studied. For short-term results, 
cryoablation (4.6% tumor-persistent disease and complication rate of 10.6%) is considered 
better than RF ablation (7.9% and 13.9%, respectively) (Weld & Landman, 2005). However, 
there are no prospective comparative studies to suggest that cryoablation is more effective 
than RF ablation for the treatment of small RCCs. RF ablation has several advantages with a 
superior relationship between the RF-probe diameter and the volume of ablated tissue 
(Mahnken et al., 2005). RF ablation also provides many potential benefits, including a low 
complication rate, reduced morbidity, shorter hospital stay, absence of an ischemic period, 
possible conscious sedation, less expensive than surgery, and the ability to avoid the higher 
risk of surgical resection in elderly patients (Lotan & Cadeddu, 2005; Mouraviev et al., 2006; 
Park et al., 2007). Furthermore, RF ablation may minimize destruction of normal renal tissue 
and thus minimizes removal of functional nephrons (Mylona et al., 2009). For the 
intermediate term, the oncologic outcomes of RF ablation appear comparable to that of 
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partial nephrectomy for small, early stage RCCs (Stern et al., 2007). However, long-term 
data is still lacking. 
2. Mechanism 
High-frequency, alternating electric current produced by the RF generator is delivered to 
target tissues through an electrode. RF current returns to the generator via grounding pads 
and thereby completes the electrical circuit. Deposition of RF energy results in molecular 
friction and heat production, leading to membrane disruption, protein denaturation, 
vascular thrombosis, and ultimately, coagulation necrosis. Thermal damage is dependent on 
both the tissue temperature achieved and the duration of heating. Heating tissue to 50°C to 
55°C for 4 to 6 minutes produces irreversible cell injury. At temperatures between 60°C and 
100°C, near-immediate coagulation necrosis is induced. At 110°C, tissue vaporizes and 
carbonizes (McAchran et al., 2005; Zagoria, 2004a). 
3. Patient selection: Indications and contraindications 
Indications for RF ablation include significant comorbidities making the patient a high 
surgical risk, pre-existing renal insufficiency, advanced age, life expectancy of more than 1 
year but less than 10 years, a solitary kidney, patients who refuse surgery, or multifocal 
RCC, such as in patients with von Hippel-Lindau disease or familial RCC (Gervais et al., 
2005b; McAchran et al., 2005). The only absolute contraindications include irreversible 
coagulopathy or acute and severe medical instability, such as sepsis (Zagoria, 2004a). 
4. Techniques 
4.1 Equipment: RF systems and electrodes 
RF generators are either temperature-based or impedance-based systems. A temperature-
based system (RITA Medical Systems, Mountain View, CA, USA) monitors tissue 
temperature by the use of thermocouples at the needle tips and determines completion of 
treatment when the tissue adjacent to the probe has reached a target temperature for a 
predetermined duration of time. Impedance-based systems (Radionics, Burlington, MA, 
USA; RadioTherapeutics, Sunnyvale, CA, USA; CelonPOWER System, Teltow, Germany) 
measure the impedance of the surrounding tissue of the electrode and RF energy is 
delivered until the impedance exceeds a critical level (Anderson et al., 2005; Desai & Gill, 
2002). To the best of our knowledge, there are no comparative clinical studies showing a 
clear advantage for the use of each system. All of these generators modulate the amount of 
electrical current delivered to the electrode. If too much RF energy is provided too quickly, 
charring occurs immediately surrounding the electrode. This charring highly increases the 
resistance of the tissue and does not allow delivery of the electric current into the tissue. 
Thus, ablated zones are decreased in size and results are less reproducible (Anderson et al., 
2005). There is a variety of electrodes: single versus multiple tined probes versus cluster, and 
wet versus dry versus cooled-tip probes. However, there are no randomized comparative 
clinical studies for the electrode types. 
4.2 Guidance and approaches 
RF ablation is performed under ultrasound (US), CT, or MR guidance for exact targeting of 
the electrode within renal tumors. Most investigators prefer CT guidance that allows 
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accurate placement of the electrode. Although US provides widespread availability, real-
time imaging, absence of ionizing radiation, low cost capabilities, and portability, US has 
some limitations for guiding electrodes. (Fig. 1, US-guided radiofrequency ablation.) In 
some cases, it is difficult to visualize lesions due to a lack of innate tissue conspicuity or 
overlying bony structures or gas-containing bowel structures. During US-guided RF 
ablation, a tumor surrounding the electrode becomes centrifugally hyperechogenic 
secondary to microbubble formation in the ablated tissue. Thus, it may be difficult to 
appreciate the difference between tumor tissue and normal tissue. Such acoustic changes 
may increase the difficulty to reposition the probe for further treatment. For renal RF 
ablation, CT has some advantages, including superior anatomic delineation, easy 
visualization of small tumors, absence of obscuring artifacts after ablation, and intravenous 
contrast enhancement to determine the adequacy of ablation (Zagoria, 2004a). (Fig. 2, CT-
guided radiofrequency ablation.)  
RF ablation can be performed via open, laparoscopic, or percutaneous approach. Open RF 
ablation is rarely used in clinical practice. Laparoscopic RF ablation performed under 
general anesthesia is typically used for anterior and medial tumors or for tumors in close 
proximity to the ureter, renal hilum, or adjacent organs. Percutaneous RF ablation can be 
performed under conscious sedation or general anesthesia (Anderson, 2005; Carraway et al., 
 
 
Fig. 1. US-guided radiofrequency. US image shows a echogenic electrode within the tumor 
(arrow). 
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Fig. 2. CT-guided radiofrequency ablation. Unenhanced CT scan shows a targeted electrode 
within the tumor (arrow). 
2009). Meta-analysis has shown that a percutaneous RF ablation procedure is safer and as 
equally effective as compared with an open or laparoscopic approach, although more than 
one treatment session may be needed to treat renal tumors completely (Hui et al., 2008). 
4.3 Pre-RF ablation biopsy 
There is no consensus on the value of performing a percutaneous biopsy prior to ablation of 
renal tumors. A pre-ablation biopsy is not required for treatment and a biopsy should be 
performed at the preference of the surgeon (Anderson et al., 2005). However, a biopsy is 
recommended if it is expected that the biopsy results will have an impact on patient 
treatment and follow-up imaging planning (Zagoria, 2004a). 
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4.4 Imaging follow-up 
Immediate follow-up imaging on postoperative day one or two is generally unnecessary 
and can cause misinterpretation, as the presence of periablation enhancement suggestive of 
reactive hyperemia may mimic the presence of a residual viable tumor on contrast-enhanced 
imaging (Carraway et al., 2009). Follow-up CT examinations are performed at 1 month, 3 
and 6 months, and then every 6 months thereafter in our institution. However, the timing of 
follow-up imaging studies varies among institutions and the optimal interval time remains 
to be determined (Gervais et al., 2005a). 
4.5 Outcomes 
4.5.1 Therapeutic efficacy 
Treatment success for RF ablation is assessed by postprocedural imaging, and is typically 
assessed by CT imaging or MR imaging at least 1 month after treatment. Imaging 
immediately after the procedure can be difficult to interpret because periablation 
inflammation may mimic the appearance of a residual viable tumor (Hines-Peralta & 
Goldberg, 2004). A definition of complete coagulation necrosis and thus a completely 
ablated tumor after RF ablation is the absence of enhancement on CT or MR images. 
Enhancement (> 10 HU or > 15% with CT and MR imaging, respectively) of any portion of 
the tumor is considered a residual viable tumor. Recurrence is defined as new enhancement 
that develops after CT or MR images have been interpreted to show complete necrosis 
(Gervais et al., 2005b; Zagoria, 2004a). Effectiveness is defined by the proportion of tumors 
without residual enhancement after one treatment session (i.e., primary effectiveness) or 
after repeated treatments (i.e., secondary effectiveness) (Hui et al., 2008). In our series, 17 
RCCs in 16 patients were subjected to RF ablation treatment. The mean tumor size was 2.2 
cm (range, 1.6-5.0 cm) and all tumors were in an exophytic location. The mean follow-up 
period was 23.8 months (range, 17-33 months). During the radiological follow-up period, 13 
tumors of 12 patients were successfully treated in one ablation session and 4 tumors of 4  
 
 
Fig. 3. Radiofrequency ablation of renal cell carcinoma. A. Contrast-enhanced CT scan 
shows low attenuated, exophytic tumor (arrow) with multiple, irregularly enhancing septa 
in the right kidney. B. Two-year follow-up contrast-enhanced CT scan after radiofrequency 
ablation treatment shows no intratumoral enhancement with decreased tumor size and 
peritumoral halo (arrow), suggesting complete ablation and no recurrence. 
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patients required more than one session on the basis on follow-up CT. (Fig. 3, 
Radiofrequency ablation of renal cell carcinoma.) One tumor required 3 sessions based on 
areas of persistent enhancement within the tumor. In addition, 7 tumors of 7 patients 
required electrode repositions, as the tumor size was too large. Technical success and 
technical effectiveness were achieved in all cases (100%). Local recurrence was not detected 
in any of the cases. On follow-up CT, all tumors showed a variable degree of size reduction 
(mean diameter, 0.6 cm; range, 0.2-1.7 cm) in comparison with pretreatment CT. No 
metastases developed in the patients during the follow-up period.  
Successful rates for complete RF ablation of small renal tumors have ranged from 82% to 
100% in recent series. Gervais et al. demonstrated that in 85 patients (100 renal tumors) 
who underwent percutaneous RF ablation, small (≤ 3 cm) peripheral tumors were 
completely ablated with 100% success; however, larger tumors (3-5 cm and > 5 cm) were 
ablated with 92% and 25% success rates, respectively (Gervais et al., 2005b). Zagoria et al. 
showed data on 125 RCCs in 104 patients who underwent percutaneous RF ablation. The 
tumor size ranged from 0.6 cm to 8.8 cm (mean size, 2.7 cm). Of 125 renal tumors, 116 
(93%) tumors were completely ablated with a mean follow-up interval of 13.8 months 
(Zagoria et al., 2007). McDougal et al. presented outcomes of 16 patients with biopsy 
proven RCCs with greater than 4-year follow-up. These investigators showed successful 
outcomes in exophytic masses smaller than 5 cm. Twelve (92.3%) of the 13 tumors treated 
had no evidence of disease (McDougal et al., 2005). Levinson et al. reported data with the 
longest follow-up to date (61.6 months). A total of 31 patients received 34 RF ablation 
treatments. Tumor sizes ranged from 1.0 cm to 4.0 cm (median size, 2.0 cm). The overall 
recurrence-free survival rate was 90.3%. There was a 100% metastasis-free rate and 
disease specific survival rate in the cohort of patients. The overall patient survival was 
71.0% (Levinson et al., 2008). 
4.5.2 Complications 
Complications are classified as major or minor based on the classification of the Society of 
Interventional Radiology with major complications requiring treatment or hospitalization 
and minor complications needing only conservative monitoring (Gervais et al., 2005a). In 
general, the overall complication rates of RF ablation have been reported from 2.8% to 
17.6% with the majority of complications being minor complications (Carraway et al., 
2009). The most common complication is hemorrhage (Gervais et al., 2005b). (Fig. 4, 
Perinephric hematoma.) 
Major complications include superficial liver laceration, significant blood loss, congestive 
heart failure, conversion to open surgery, hemorrhage leading to nephrectomy, pulmonary 
embolism, myocardial infarction, pancreatic injury requiring surgery, ureteropelvic junction 
obstruction, ureteropelvic junction injury requiring nephrectomy, urine leakage, 
pneumonia, pelvic vein thrombosis, hematuria with significant blood clots and urinary 
obstruction, persistent muscle weakness, ureteric thermal injury requiring stent insertion, 
persistent urinoma, proximal ureteral stricture, cutaneous–urinary fistula, colon–nephric 
fistula, colon injury, and needle tract seeding. Minor complications include perirenal 
hematoma, transient hematuria, wound infection, postoperative ileus, hydronephrosis, 
wound separation, probe site pain or paresthesia, infection, an increased serum creatinine 
level, and transient neuropathy (Hui et al., 2008). 
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Fig. 4. Perinephric hematoma. Contrast-enhanced CT scan shows hematoma (arrow) in the 
right perinephric space after radiofrequency ablation treatment. 
5. Factors influencing successful ablation 
Tumor size and location are the two most important factors that determine whether RCCs can 
be treated successfully. Zagoria et al. found that the major determinant of successful RF 
ablation was tumor size. There was no correlation between the success of ablation and tumor 
location, histology, and the presence of renal disease (Zagoria et al., 2004b). A recent series 
showed that RF ablation could be reliably performed to treat RCCs smaller than 3.7 cm 
(Zagoria et al., 2007). However, upper size limits for consideration of renal tumors for RF 
ablation have not been determined. Various investigators have set this limit from 2.5 cm to 4.0 
cm. (Gervais et al., 2005b). Despite advances in electrode design, successful ablation of tumors 
greater than 4 cm in diameter has been challenging. However, larger tumors require multiple 
overlapping ablations (Park et al., 2008). The location of the tumor can also influence the 
success of RF ablation. Even large exophytic tumors are usually treated successfully. However, 
central tumor ablation fails more frequently because of a heat sink effect where regional 
vascular flow reduces the extent of the thermally induced coagulation (Yoon et al., 2009). 
Gervais et al. found that both a small size and noncentral location are independent significant 
predictors of complete necrosis after a single ablation session, based on the use of multivariate 
analysis (Gervais et al., 2005b). The gauge and configuration of the electrode tip, intensity and 
length of the current, duration of energy applied, and certain characteristics of the tissue that is 
being ablated determine the extent of tissue ablation. Optimization of these factors is 
mandatory for success of RF ablation (McAchran et al., 2005). 
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Many clinical and experimental studies have reported promising short and intermediate-
term outcomes with RF ablation for the treatment of small renal tumors. However, multi-
institutional, high volume, long-term follow-up data on cancer-specific survival are not as 
yet available and such data are required before RF ablation can be considered as a standard 
of management. A further prospective or a randomized trial comparing RF ablation with 
nephron-sparing surgery such as a partial nephrectomy is needed. Optimal techniques to 
perform RF ablation for renal tumors are still evolving. We are awaiting further studies on 
factors that influence successful ablation. Additionally, future trials should also use 
standard terminology. Further studies for RF ablation will likely aim to alleviate existing 
shortcomings by the improvement of imaging and guidance, by increasing the size of the 
ablation zone, and by improving performance for problematic cases. 
7. Conclusion 
Although nephron-sparing surgery such as laparoscopic partial nephrectomy must remain 
standard therapy for patients with small, localized RCCs, RF ablation for the treatment of 
RCC is a very promising technique that should be considered as a treatment option for 
patients with small renal tumors who are not good surgical candidates. For indications, RF 
ablation can be applied successfully for the treatment of refractory hematuria resulting from 
RCC, for local recurrence of RCC, and for isolated metastases from RCC (Zagoria, 2004a). RF 
ablation is increasingly performed and the use of RF ablation has become widespread due to 
comparable encouraging short and intermediate-term outcomes and a relatively low 
incidence of major complications. However, critical use of this procedure is emphasized 
until more long-term follow-up results are available. Although a number of controversies 
currently remain, we believe that image-guided RF ablation is a safe and effective treatment 
option with a very low complication rate for small exophytic renal tumors in selected 
patients. 
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